MyFinsight
Home
Blog
About
Contact
Download
Download image
Sales and maturities
of marketable...
$19,252K
Proceeds from exercise of
pre-funded warrants
$2K
Net cash provided by
(used in) investing...
$19,252K
Net cash provided by
financing activities
$2K
Net decrease in
cash, cash...
-$365K
Canceled cashflow
$19,254K
Stock-based compensation
expense
$2,413K
Prepaid expenses, other
current and non-current...
-$778K
Non-cash lease expense
$374K
Accretion of debt discount
$230K
Depreciation and
amortization expense
$223K
Net cash used in
operating activities
-$19,599K
Canceled cashflow
$4,018K
Effect of exchange rate
changes on cash, cash...
-$20K
Net loss
-$20,241K
Accrued expenses and
other long-term...
-$1,549K
Accounts payable
-$624K
Accounts receivable
$541K
Lease liabilities
-$259K
Inventory
$158K
Other
$106K
Change in fair value of
warrant liability
-$80K
Deferred revenue
-$59K
Back
Back
Cash Flow
X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc (XFOR)
source: myfinsight.com